openPR Logo
Press release

Tumor Necrosis Factor Inhibitors Market & TNF Inhibitors Clinical Pipeline Outlook 2022

07-07-2017 10:12 AM CET | Health & Medicine

Press release from: Kuick Resarch

Tumor Necrosis Factor Inhibitors Market & TNF Inhibitors

The search for the effective therapeutic approaches in the modulation of the TNF has been focus of the research efforts. Approximately 1 Million people in the worldwide either undergoing the treatment or have been treated with the TNF inhibitors which are available in the pharmaceutical market which surrounding the indications that include the rheumatoid arthritis, psoriatic arthritis, psoriasis and inflammatory bowel diseases.

The neutralization of the TNF signaling can be achieved at the different levels, level of the ligand, level of the receptors and of the intracellular signal pathways. The approved anti-TNF therapies all interfere at the level of the ligand by directly binding to TNF and thus by preventing its interaction with both the TNF receptors. The five structurally different anti-TNF drugs are approved for the treatment of the various inflammatory diseases.

The drugs which are commonly used as immunosuppressant for example cyclosporine A and dexamethasone which display the TNF-α modulation, although their effects are related with considerable toxicity. However, as the mechanisms that comprise the production of TNF and its activity on cells, it become well understood, more specific strategies for the inhibition of the cytokine emerge. Examples contain the development of new therapeutic agents and the alteration of the existing ones, seeking the lower toxicity, greater potency and a larger number of clinical substitutions.

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-tumor-necrosis-factor-inhibitors-market-and-clinical-pipeline-outlook-2022.php

Report Table of Contents

Introduction to Tumor Necrosis Factor (TNF)
1.1 Basic Structure of the Tumor Necrosis Factor (TNF) Molecule
1.2 Significance of Tumor Necrosis Factor for the Biosynthesis Regulation
1.2.1 Regulation of TNF Biosynthesis at the Transcriptional Level
1.2.2 Regulation the TNF at the Receptor Level
1.3 Tumor Necrosis Factor Receptors

Tumor Necrosis Factor Receptor Signaling Pathway
2.1 Tumor Necrosis Factor Receptor1 (TNFR1) Signaling
2.2 Tumor Necrosis Factor Receptor 2 (TNFR 2) Signaling

Overview of Tumor Necrosis Factor Inhibitors
3.1 Mechanism of Action of Tumor Necrosis Factor Inhibitors
3.2 Mechanism of Action of Remicade in the Inflammatory Diseases
3.3 Mechanism of Action of the Etanercept
3.4 Mechanism of Action of Humira

Approaches Used in Development of Anti-TNF
4.1 Monoclonal Antibody Approach
4.2 Recombinant DNA Technology Approach

Function of TNF in Immune Mediated Inflammatory Diseases
5.1 Rheumatoid Arthritis
5.2 Crohn's Disease
5.3 Psoriasis and Psoriatic Arthritis

Involvement of TNF and its Receptor in Neurodegenerative Disorders
6.1 Alzheimer’s Diseases
6.2 Parkinson’s Diseases
6.3 Ischemic Stroke
6.4 Multiple Sclerosis

Role of the Tumor Necrosis Factor in the Development of the Cancer
7.1 Introduction
7.2 Tumor Necrosis Factor as Carcinogen
7.3 Tumor Necrosis Factor as an Anti-Cancer Agent

TNF Inhibitors Market Overview
8.1 Market of Anti-TNF Blockbuster Drugs
8.1.1 Market of Humira
8.1.2 Market of Enbrel
8.1.3 Market of Remicade
8.2 Global Tumor Necrosis Factor Inhibitors Pipeline Overview

Global TNF Inhibitors Market Dynamics
9.1 Accelerative Parameters to the TNF Inhibitor Market
9.2 Challenges to the TNF Inhibitor Market

Future Implications of TNF Inhibitor Market

Global Tumor Necrosis Factor Inhibitors Pipeline by Company, Indication and Phase
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Clinical
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
11.10 Preregistration
11.11 Registered

Marketed Tumor Necrosis Factor Inhibitors Clinical Insight
12.1 Lumbricus Rubellus Extract (Disolf)
12.2 Certolizumab Pegol (Cimzia, Simziya)
12.3 Apremilast (Otezla)
12.4 Lenalidomide (Ladevina, Revlimid)
12.5 Adalimumab (Humira, Raheara)
12.6 Etanercept (Enbrel)
12.7 Infliximab Biosimilar (Inflectra, Remsima)
12.8 Adalimumab Biosimilar
12.9 Pomalidomide (Imnovid, Pomalyst)
12.10 Belimumab (Benlysta)
12.11 Etanercept Biosimilar (Infinitam)
12.12 Golimumab (Simponi)
12.13 Infliximab Biosimilar (Infimab)
12.14 Infliximab (Remicade)
12.15 Etanercept Biosimilar (Intacept)
12.16 Iguratimod (Careram, Kolbet)
12.17 Thalidomide (Thaled, Thalidomide Celgene, Thalomid)
12.18 Infliximab Biosimilar
12.19 Adalimumab Biosimilar (Exemptia)
12.20 Etanercept Biosimilar (Iran)
12.21 Etanercept Biosimilar (Etacept, Etanar, Yisaipu)
12.22 Iguratimod
12.23 Anti-Tumour Necrosis Factor-Alpha Antibody Oral
12.24 Pentoxifylline (Claudicat, Dospan Pento, Elorgan, Pentoxifilina, Trental)
12.25 Sho-seiryu-to

TNF Inhibitors Suspended in Clinical Pipeline
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended

Competitive Landscape
14.1 AbbVie
14.2 Ablynx
14.3 Apogenix
14.4 AryoGen Biopharma
14.5 Bionovis
14.6 CASI Pharmaceuticals
14.7 Celltrion
14.8 Celgene Corporation
14.9 Delenex Therapeutics
14.10 Dexa Medica
14.11 EPIRUS Biopharmaceuticals
14.12 Janssen Biotech
14.13 GlaxoSmithKline
14.14 HanAll Biopharma
14.15 Intas Pharmaceuticals
14.16 LEO Pharma
14.17 LG Life Sciences
14.18 MedImmune
14.19 Momenta Pharmaceuticals
14.20 Novartis
14.21 PROBIOMED
14.22 Reliance Life Sciences
14.23 Sandoz
14.24 Samsung Bioepis
14.25 Sanofi-Aventis
14.26 Shanghai CP Guojian Pharmaceutical
14.27 Shanghai Pharmaceuticals
14.28 Simcere Pharmaceutical
14.29 Toyama Chemical
14.30 Tsumura
14.31 UCB
14.32 Zydus Cadila

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tumor Necrosis Factor Inhibitors Market & TNF Inhibitors Clinical Pipeline Outlook 2022 here

News-ID: 613444 • Views: 395

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for TNF

TNF Inhibitors Global Industry Report - History, Present and Future 2025
The global market size of TNF Inhibitors is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023. There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment. For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented
TNF Inhibitors Market Key Drivers & On-going Trends 2017 – 2025
TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflammation-causing substance. TNF inhibitor drugs are employed to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. Generally, in the healthy person, the TNF
TNF Inhibitors Market Key Drivers & On-going Trends 2017 - 2025
TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflammation-causing substance. View Report- https://www.transparencymarketresearch.com/tnf-inhibitors-market.html TNF inhibitor drugs are employed to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. Generally, in the healthy person, the
Global Pharmaceutical Market Landscape for TNF Inhibitors - A Pipeline Analysis …
"The Report TNF Inhibitors - A Pipeline Analysis Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" TNF Inhibitors: An insight The TNF inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global TNF inhibitors market. The anti-TNF drugs are among the top 10 global blockbuster drugs and have dominated the global pharmaceutical market landscape for many years. The report
TNF Inhibitors - A Pipeline Analysis Report
"The Report TNF Inhibitors - A Pipeline Analysis Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" TNF Inhibitors: An insight The TNF inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global TNF inhibitors market. The anti-TNF drugs are among the top 10 global blockbuster drugs and have dominated the global pharmaceutical market landscape for many years. The report
Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2017
“Tumor Necrosis Factor Alpha (TNF-a) Inhibitors-Pipeline Insights 2017″, report provides comprehensive analysis of TNF-a drug candidates currently undergoing clinical trials. The report covers detailed drug profiles of potential TNF-a inhibitors across various clinical development phases including – discovery, pre-clinical, IND, Phase I, Phase II, Phase III and Pre-registration. Report also includes the pipeline products’ clinical trial data along with information on other development activities including technology, licensing, collaborations, acquisitions, funding,